Evaluating Risk of Recurrent Venous Thromboembolism During the Anticoagulation Period in Patients with Malignancy

Evaluating Risk of Recurrent Venous Thromboembolism During the Anticoagulation Period in Patients with Malignancy

Show other versions (3)

Background - Current guidelines suggest that all cancer patients with venous thrombosis be treated with long-term low molecular weight heparin. Whether treatment strategies should vary according to clinical characteristics remains unknown. // Systematic review - A systematic review was performed to...

Full description

Bibliographic Details
Main Author: Louzada, Martha
Other Authors: Wells, Philip
Language:en
Published: Université d'Ottawa / University of Ottawa 2011
Subjects:
venous thromboembolism recurrence
cancer
malignancy
risk factors
clinical prediction rule
Online Access:http://hdl.handle.net/10393/19827
http://dx.doi.org/10.20381/ruor-4465

Internet

http://hdl.handle.net/10393/19827
http://dx.doi.org/10.20381/ruor-4465

Similar Items